Breakthrough in Human Liver Model Using Stem Cells
In an exciting scientific development, researchers have successfully developed a fully human mini liver system using stem cells and patient-specific immune cells. This advanced model allows for the study of why some individuals experience severe immune-related liver injuries from drugs generally considered safe.
Developing a Model for Immune Liver Injury
Researcher Fadwa Alabdullawi Sosi, one of the study’s authors, discussed the team’s goal of creating a human system that reflects how the liver and immune system interact in patients. By integrating patient-specific genes and immune responses, the model can explain why certain drugs cause liver injuries in only a small subset of individuals.
The new platform integrates liver organoids made from induced pluripotent stem cells with donor-specific CD8⁺ T cells, resulting in a human system that mirrors the genetic and immune diversity found in actual patients.
Practical Application of the Model
As an example of the model’s effectiveness, researchers replicated liver damage caused by the antibiotic flucloxacillin, which occurs only in individuals carrying the HLA-B*57:01 gene. The model accurately reproduced markers of immune liver injury, such as T cell activation, cytokine release, and liver cell damage.
Dr. Magdalena Kasendra, Director of Research and Development at CuSTOM Center, explained that the goal is to bring human biology into the lab in a scalable and reproducible way that benefits patients. By linking basic stem cell biology with applied toxicology, this model is approaching a transformation in how drugs are developed and tested.
Innovation in Organoid Science
This new system builds on the previous work of Dr. Takanori Takebe, who developed methods to generate human liver organoids from induced pluripotent stem cells. By advancing these techniques into a matrix-free microarray system and integrating them with patient-specific immune cells, the CuSTOM Accelerator team has turned this scientific breakthrough into a scalable precision toxicology tool.
Collaboration with Roche played a key role in the project’s success, combining the hospital’s scientific expertise with Roche’s experience in translational toxicology.
The Growing Ecosystem of Organoid Medicine
Since 2010, Cincinnati Children’s Hospital has been a global leader in organoid medicine, after its scientists created the first functional human intestinal organoids. Under Kasendra’s leadership, the CuSTOM Center collaborates with tech and biopharmaceutical companies to translate these scientific advancements into practical solutions for drug safety, precision medicine, and regenerative therapy.
The CuSTOM Accelerator team continues to work on automating organoid testing and enabling comprehensive screening across large, genetically diverse donor groups, which will capture the full spectrum of human diversity.
Conclusion
This work represents a significant step toward turning science into practical tools for health improvement. By combining biology, engineering, and clinical insight, researchers are getting closer to predicting how real patients will respond to new treatments before they reach the clinic. The ultimate goal remains to develop more effective, inclusive, and personalized therapies.